FluBlok, a recombinant hemagglutinin influenza vaccine

FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg‐based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA t...

Full description

Saved in:

Bibliographic Details
Published in:	Influenza and other respiratory viruses Vol. 2; no. 6; pp. 211 - 219
Main Authors:	Cox, Manon M.J., Patriarca, Peter A., Treanor, John
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Publishing Ltd 01-11-2008
Subjects:	Adolescent Adult Aged Aged, 80 and over Animals Baculovirus cell culture Double-Blind Method Female hemagglutinin Humans influenza Influenza Vaccines - administration & dosage Influenza Vaccines - adverse effects Influenza Vaccines - immunology Male Middle Aged Placebos - administration & dosage Reviews safety United States vaccine Vaccines, Synthetic - administration & dosage Vaccines, Synthetic - adverse effects Vaccines, Synthetic - immunology Young Adult United States
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	FluBlok, a recombinant trivalent hemagglutinin (HA) vaccine produced in insect cell culture using the baculovirus expression system, provides an attractive alternative to the current egg‐based trivalent inactivated influenza vaccine (TIV) manufacturing process. FluBlok contains three times more HA than TIV and does not contain egg‐protein or preservatives. This review discusses the four main clinical studies that were used to support licensure of FluBlok under the ‘Accelerated Approval’ mechanism in the United States.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1750-2640 1750-2659
DOI:	10.1111/j.1750-2659.2008.00053.x